XN has also been shown to improve cognitive performance and reduce neuropathology in 9-month-old male mice with transgenic expression of human amyloid precursor protein and presinilin 1 with familiar Alzheimer's disease mutations (Sun et al., 2021). Here, APP is linked to early-onset autosomal dominant Alzheimer disease.